Analyzing...
Loading company...
Pfizer Ltd. engages in the business of manufacturing, marketing, trading, import and export of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 1,702 full-time employees. The firm is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The firm has its own manufacturing facility at Goa. The firm has various independent contract/third party manufacturers based across India. Its product portfolio includes vaccine, anti-infectives, cardiac, pain, maternal nutrition, gastrointestinal, contraceptives, anti-inflammatory, nutrition and immunity, and respiratory. The firm's vaccine business is focused on Prevenar 13, a pneumococcal conjugate vaccine that is administered to infants who are six weeks and older as part of primary vaccination, toddlers, adolescents, adults, and elderly population. Its inflammation and immunology portfolio includes two advanced therapies, which cater to patients suffering from diseases related to chronic immune system such as rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis and ulcerative colitis.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹2,520 Cr revenue.
COGS 35.1%, employees 14.6%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 17.2%▲ | 10.3% |
| ROCE | 22.9%▲ | 13.7% |
| Net Margin | 26.7%▲ | 7.6% |
| EBITDA Margin | 38.5%▲ | 15.4% |
| Debt To Equity | 0.00x▼ | 0.15x |
Revenue segment breakdown not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2,520 Cr +10.4% | ₹2,281 Cr +4.0% | ₹2,193 Cr -9.6% | ₹2,425 Cr -7.1% | ₹2,611 Cr +16.6% | ₹2,239 Cr +4.0% | ₹2,152 Cr +3.4% | ₹2,082 Cr |
| Other Income | ₹188 Cr +9.1% | ₹172 Cr -4.6% | ₹181 Cr +78.6% | ₹101 Cr +61.3% | ₹63 Cr -22.8% | ₹81 Cr -55.9% | ₹184 Cr +9.9% | ₹167 Cr |
| Total Income | ₹2,708 Cr +10.4% | ₹2,454 Cr +3.4% | ₹2,374 Cr -6.0% | ₹2,526 Cr -5.5% | ₹2,674 Cr +15.3% | ₹2,320 Cr -0.7% | ₹2,336 Cr +3.9% | ₹2,249 Cr |
| COGS | ₹884 Cr +9.1% | ₹810 Cr +2.3% | ₹793 Cr -9.3% | ₹874 Cr -7.8% | ₹948 Cr +18.8% | ₹798 Cr +0.7% | ₹792 Cr +5.9% | ₹748 Cr |
| ₹1,683 Cr +4.5% | ₹1,610 Cr -1.5% | ₹1,636 Cr -5.7% | ₹1,735 Cr -8.7% | ₹1,901 Cr +15.1% | ₹1,651 Cr -2.5% | ₹1,693 Cr +6.6% | ₹1,589 Cr | |
| Profit Before Tax | ₹976 Cr -4.0% | ₹1,016 Cr +36.2% | ₹746 Cr -9.5% | ₹824 Cr +6.6% | ₹773 Cr +15.6% | ₹669 Cr +4.1% | ₹642 Cr -2.6% | ₹660 Cr |
| Exceptional Items | (₹49 Cr) ↓ Decline | ₹173 Cr | ₹8 Cr -75.9% | ₹33 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹253 Cr +1.9% | ₹248 Cr +27.6% | ₹195 Cr -2.7% | ₹200 Cr +24.8% | ₹160 Cr -6.3% | ₹171 Cr +28.3% | ₹133 Cr -42.2% | ₹231 Cr | |
| Net Profit | ₹722 Cr -5.9% | ₹768 Cr +39.2% | ₹551 Cr -11.6% | ₹624 Cr +1.9% | ₹613 Cr +23.1% | ₹498 Cr -2.3% | ₹509 Cr +18.7% | ₹429 Cr |
| Other Comprehensive Income | ₹4 Cr +418.9% | ₹0.74 Cr -86.4% | ₹5 Cr +51.0% | ₹4 Cr -49.7% | ₹7 Cr ↑ Recovery | (₹0.96 Cr) +89.2% | (₹9 Cr) ↓ Decline | ₹1 Cr |
| EPS | ₹157.92 | ₹167.79 | ₹120.52 | ₹136.38 | ₹133.90 | ₹108.77 | ₹111.29 | ₹93.79 |
| Diluted Shares | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
No earnings call transcripts available.
Pfizer Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 28, 2026. Further, the company has informed the Exchange regarding voting results.
Pfizer Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 28, 2026
Pfizer Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Pfizer Limited has informed the Exchange regarding Change in Director(s) of the company.
The Exchange has sought clarification from Pfizer Limited with respect to recent news item captioned Pfizer suspends Premarin vaginal cream in India, raising concerns over menopause care.. The respon...
The Exchange has sought clarification from Pfizer Limited with respect to recent news item captioned Pfizer suspends Premarin vaginal cream in India, raising concerns over menopause care.. The respon...
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.
Pfizer Limited has informed the Exchange regarding 'Letter to shareholders providing the weblink to access the Annual Report for Financial Year 2025 26.'.
Pfizer Limited has informed the Exchange about Copy of Newspaper Publication
Pfizer Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 20...
Pfizer Limited has informed the Exchange about Copy of Newspaper Publication
Pfizer Limited has informed the Exchange about Delay/default in the payment of fines/penalties/dues etc. to authority
Pfizer Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Pfizer Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
Pfizer Limited has informed the Exchange about Copy of Newspaper Publication
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.